Houston space tech co. revises timeline for commercial space station development with NASA partnership

new game plan

Axiom Space is accelerating its development of a commercial space station, revising plans with NASA to launch key modules by 2028 and transition to an independent Axiom Station before the ISS retires in 2030. Image via NASA

Houston-based Axiom Space is accelerating its development of a commercial space station.

NASA awarded Axiom a contract in January 2020 to develop a space station for commercial use. Initially, the station was supposed to be attached to the International Space Station. Later, it was supposed to become a free-flying space station in low-earth orbit before retirement of the current space station in 2030.

In coordination with NASA, Axiom Space has modified the plan.

Initially, Axiom planned to attach its first module, Habitat 1, to the space station, followed by three additional modules. Under the new scenario, the payload, power, and thermal modules will be launched first. This will enable the modules to join the current space station as early as 2028, becoming a free-flying station called Axiom Station.

“The International Space Station has provided a one-of-a-kind scientific platform for nearly 25 years,” says Dana Weigel, manager of the International Space Station program at NASA’s Johnson Space Center.

“As we approach the end of [the] space station’s operational life," she continues, "it’s critically important that we look to the future of [low-earth orbit] and support these follow-on destinations to ensure we continue NASA’s presence in microgravity, which began through the International Space Station.”

In free flight, Axiom will continue assembling the commercial destination, adding the Habitat 1 module, an airlock, the Habitat 2 module, and a research and manufacturing lab.

“We were ready to answer the call when NASA asked us to relook at our space station development plan,” Mark Greeley, Axiom Space COO and Axiom Station program manager, says in a statement from Axiom. “Our ongoing assessment of the assembly sequence revealed opportunities for flexibility and enhancements. With the International Space Station needing to protect for the ability to accommodate a deorbit vehicle on station, we were able to accelerate this work to support the program’s requirements.

“NASA has been extremely collaborative and supportive of the new plan as it addresses its deorbit operational concerns and preserves critical capabilities currently utilized on the International Space Station,” he adds. “This revised approach not only aligns with U.S. objectives but also delivers immediate value for our customers and investors.”

The Axiom's Payload Power Thermal Module primary structure is being constructed by Thales Alenia Space in Turin, Italy, and then moved to Houston by fall 2025, where the rest of the internal structure and systems will be integrated at Axiom Space facilities.

“Working with leading experts like Thales Alenia, who have a proven record in module development and a strong relationship with NASA, is integral to our operations and vision," Tejpaul Bhatia, Axiom Space chief revenue officer, says.

“By engaging and integrating with a network of partners from around the world, we access cutting-edge technologies and innovative solutions that enhance our capabilities and supply chain,” Bhatia adds. “Our customer base is truly global, including governments, private entities, and research institutions. This diversity enables us to meet a wide range of needs and reinforces our belief that space exploration is a collective endeavor for the benefit of all of humanity.”

Axiom has revised its plan for its commercial space station. Image via Axiom

From Your Site Articles
The scalable engine technology will be instrumental for Intuitive Machines' lunar missions. Photo courtesy of Intuitive Machines

Houston space tech company reaches major milestone for engine technology

fired up

A Houston company that's creating the next generation of space exploration technology is celebrating a new milestone of one of its technologies.

Intuitive Machines reports that its VR900 completed a full-duration hot-fire test, qualifying it for its IM-2 lunar mission. With the qualification, the company says its VR3500, an engine designed for larger cargo class landers, also advances in development.

The engine technology is designed, 3D-printed, and tested all at Intuitive Machines' Houston facility, which opened in the Houston Spaceport last year.

Intuitive Machines CEO Steve Altemus says in a news release that the company's goal was to lead the way in scalable deep space engines as the industry heads toward lunar missions.

“This validated engine design meets current mission demand and paves the way for our VR3500 engine for cargo delivery such as lunar terrain vehicles, human spaceflight cargo resupply, and other infrastructure delivery," Altemus continues. "We believe we’re in a prime position to build on our successful development and apply that technology toward current contracts and future lunar requirements for infrastructure delivery.”

Earlier this year, Intuitive Machines was one of one of three companies selected for a $30 million NASA contract for the initial phase of developing a rover for U.S. astronauts to traverse the moon’s surface.

Another Houston company has seen success with its engine testing. In March, Venus Aerospace announced that it's successfully ran the first long-duration engine test of their Rotating Detonation Rocket Engine in partnership with Defense Advanced Research Projects Agency, or DARPA.

Intuitive Machines is one of three companies chosen by NASA to perform preliminary work on building a lunar terrain vehicle. Photo via NASA.org

NASA awards $30M to Houston space tech company to develop lunar rover

moon rider

Houston-based space technology company Intuitive Machines has landed a $30 million NASA contract for the initial phase of developing a rover for U.S. astronauts to traverse the moon’s surface.

Intuitive Machines is one of three companies chosen by NASA to perform preliminary work on building a lunar terrain vehicle that would enable astronauts to travel on the moon’s surface so they can conduct scientific research and prepare for human missions to Mars.

The two other companies are Golden, Colorado-based Lunar Outpost and Hawthorne, California-based Astrolab.

NASA plans to initially use the vehicle for its Artemis V lunar mission, which aims to put two astronauts on the moon. It would be the first time since the Apollo 17 mission in 1972 that astronauts would step foot on the lunar surface.

The Artemis V mission, tentatively set for 2029, will be the fifth mission under NASA’s Artemis program.

“This vehicle will greatly increase our astronauts’ ability to explore and conduct science on the lunar surface while also serving as a science platform between crewed missions,” says Vanessa Wyche, director of NASA’s Johnson Space Center in Houston.

Intuitive Machines says the $30 million NASA contract represents its entrance into human spaceflight operations for the space agency’s $4.6 billion moon rover project. The vehicle — which Intuitive Machines has dubbed the Moon Reusable Autonomous Crewed Exploration Rover (RACER) — will be based on the company’s lunar lander.

“Our global team is on a path to provide essential lunar infrastructure services to NASA in a project that would allow [us] to retain ownership of the vehicle for commercial utilization during periods of non-NASA activity over approximately 10 years of lunar surface activity,” says exploration,” says Steve Altemus, CEO of Intuitive Machines.

Intuitive Machines’ partners on the RACER project include AVL, Boeing, Michelin, and Northrop Grumman.

Intuitive Machines plans to bid on the second phase of the rover project after finishing its first-phase feasibility study. The second phase will involve developing, delivering, and operating the rover.

In February, Intuitive Machines became the first private company to land a spacecraft on the moon with no crewmembers aboard. NASA was the key customer for that mission.

A Houston company's technology will help space operators predict coronal mass ejections. Photo via nasa.gov

Houston extended reality company pivots, secures NASA contract

space tech

Following a rebrand, a Houston tech startup has secured a NASA contract for space weather technology.

Dauntless XR received a contract from NASA to advance its spatial computing platform, Aura. The technology uses satellite sensor data and mixed reality to help space operators with weather forecasting, including solar activity.

The company, which was founded by Lori-Lee Elliott as Future Sight AR in 2018 to focus on industrial construction, made a pivot to the space and defense industries and rebranded last year.

"We are in an incredibly interesting stage of space exploration, between record-breaking numbers of satellite launches, missions to the moon and Mars, and even returning asteroid samples to Earth," says Elliott, who serves as CEO, in the release. "With space weather, we are presented with an opportunity to make incredibly complex data easily accessible and provide a platform for innovation — and collaboration — for the space economy and space exploration."

The company is tasked with an extended reality space weather application. Per the release, the app will first be available on the Apple Vision Pro and the Meta Quest devices.

"Our first release will include a special edition of our Aura application with a 3D immersive experience visualizing coronal mass ejections, or CMEs, coming off the sun," the company explains in a blog post. "When a CME hits Earth, it produces auroras, but can also cause power outages, knock out radio signals & GPS, and interfere with rocket launches. As the space economy grows and more people use space data, we hope that our apps make that data easy to access and understand."

The company has also received $1.5 million in United States Air Force contracts. This included two SBIR II contracts that "focused on mixed reality assisted workflows, training and mission planning," according to Dauntless XR. Elliott is based in Houston and the company has offices in Texas, Georgia, Florida, and Hawaii.

Lori-Lee Elliott founded Dauntless XR. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings